Invention Grant
- Patent Title: Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through CD28
-
Application No.: US15035571Application Date: 2014-12-07
-
Publication No.: US09963497B2Publication Date: 2018-05-08
- Inventor: Raymond Kaempfer , Anat Shirvan , Gila Arad
- Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD , ATOX BIO LTD.
- Applicant Address: IL Jerusalem IL Ness Ziona
- Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD,ATOX BIO LTD.
- Current Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD,ATOX BIO LTD.
- Current Assignee Address: IL Jerusalem IL Ness Ziona
- Agency: Browdy and Neimark, PLLC
- International Application: PCT/IL2014/051067 WO 20141207
- International Announcement: WO2015/083173 WO 20150611
- Main IPC: C07K14/705
- IPC: C07K14/705 ; A61K38/04 ; A61K38/17 ; A61K45/06 ; A61K38/00

Abstract:
The present disclosure relates to a method for the treatment of a non-pathogen associated inflammatory disorders in a subject in need thereof, comprising administering to said subject an isolated peptide which specifically binds to an amino acid sequence within the dimer interface of a T cell costimulatory pathway member, particularly the T cell costimulatory pathway members CD28 and CTLA4. The present disclosure also relates to pharmaceutical compositions comprising the isolated peptide and to use of the peptide in treating of a non-pathogen associated inflammatory disorders.
Public/Granted literature
- US20160289295A1 REDUCTION OF INFLAMMATORY DISEASE SYMPTOMS BY SHORT PEPTIDES THAT INHIBIT SIGNALING THROUGH CD28 Public/Granted day:2016-10-06
Information query